<DOC>
	<DOCNO>NCT00004755</DOCNO>
	<brief_summary>OBJECTIVE : Compare efficacy side effect allopurinol versus glucantime versus allopurinol/glucantime patient Brazil cutaneous leishmaniasis .</brief_summary>
	<brief_title>Allopurinol , Glucantime , Allopurinol/Glucantime Cutaneous Leishmaniasis Brazil</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize study . Patients stratify participate institution . One group treat daily intramuscular injection glucantime . Patients less complete response Day 21 continue treatment lesion heal completely maximum 60 day . Patients progressive disease Day 40 remove study . The second group treat daily oral allopurinol . Patients partial response Day 21 continue treatment lesion heal completely . Patients stable progressive disease Day 21 unhealed lesion Day 56 cross glucantime therapy . Accrual group close 6/96 . The third group receive allopurinol glucantime . Patients follow 3 , 6 , 9 month , annually least 5 year .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Parasitologically confirm cutaneous leishmaniasis ( lesion le 3 month duration ) No mucocutaneous leishmaniasis No prior leishmaniasis Prior/Concurrent Therapy No prior treatment leishmaniasis Patient Characteristics Hepatic : No clinical laboratory evidence hepatic disease Renal : No clinical laboratory evidence renal disease No hyperuricemia gout Cardiovascular : No clinical , electrocardiographic , laboratory evidence cardiac disease Other : No allergy contraindication allopurinol glucantime ; No concurrent medication might interact study drug , e.g . : probenecid , warfarin , azathioprine ; No skin rash ; No malnutrition ; No medical contraindication protocol therapy ; No pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>dermatologic disorder</keyword>
	<keyword>environmental/toxic disorder</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>leishmaniasis</keyword>
	<keyword>rare disease</keyword>
</DOC>